Fidia Farmaceutici enters the Polish market
Fidia Farmaceutici, has entered the Polish pharma market by acquiring the Polish Business of U.S. based Unipharm Polish affiliate. This is another step in strengthening the company’s position on the European market.
Fidia Farmaceutici announces its entry into the Polish market and the foundation of its Polish affiliate, Fidia Pharma Polska.
For more than 75 years, Fidia has been successively expanding its presence by building a network of subsidiaries and working with commercial partners and distributors in the pharmaceutical and biomedical sectors. Today, it operates in more than 100 markets worldwide with a wide range of products in its portfolio that are mostly based on natural Hyaluronic Acid and owns more than 1100 patents involving Hyaluronic Acid with different molecular weights, industrial processes, pharmaceutical formulations, compositions, and applications.
Recently, Fidia founded its Polish affiliate Fidia Pharma Polska and acquired some eye care products and a Vitamin D-based nutritional supplement along with a branch of the Polish affiliate of Unipharm, privately owned pharmaceutical company headquartered in the U.S. specializing in the development and marketing of over-the-counter (OTC) drugs and nutritional products.
As a matter of fact, Fidia is recognized as the Italian leader in ophthalmology and its portfolio in this therapeutic area includes products for the treatment of eye diseases such as dry eye, accommodative asthenopia, ocular infection and inflammation, corneal oedema, vitreous pathologies, macular degeneration, diabetic retinopathy, glaucoma and keratoconus.
– Entering the Polish market is another important step in strengthening our position in the European market, says Carlo Pizzocaro, CEO of Fidia Farmaceutici. – We are pleased to invest in a country with such a great potential, a high development rate and a steadily growing economy. We are convinced that our presence in Poland will contribute to improving access to innovative treatment therapies for Polish healthcare professionals and patients and we hope to do so also by offering further therapeutic solutions soon. –
Fidia Farmaceutici is constantly engaged in research and development of new therapeutic options to provide increasingly innovative healthcare solutions. Among the studies under development worth mentioning are a cutting-edge drug for the treatment of patients with carcinoma in situ (CIS) of the bladder and for the treatment of malignant mesothelioma for which the U.S. Food and Drug Administration granted Orphan Drug Designation status. A worldwide phase 3 study is ongoing in centers of excellence including selected Polish sites.
Fidia is also developing a treatment based on novel collagenase from Vibrio alginolyticus, which received the Orphan Drug Designation by the US FDA as well, for the treatment of Dupuytren’s contracture, and is studying its applications also for other fibroproliferative diseases, such as Peyronie’s disease.